Alembic Pharma Q3 FY26 results up, Rs 42 cr Labour Codes exceptional item
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharma posted Q3 FY26 consolidated revenue of Rs 1,876.31 cr, up 10.8 percent YoY. 9-month revenue rose 12.1 percent to Rs 5,497.18 cr; PAT grew 10.7 percent to Rs 472.07 cr. Q3 PAT dipped to Rs 132.97 cr due to a Rs 42.23 cr exceptional charge from Labour Codes impact on gratuity and leave. Rajkumar Baheti to be Non-Executive Director from April 1, 2026. Auditor review is unqualified.
Revenue growth solid; one-time Labour Codes charge dents headline Q3 PAT. Director change is a planned handover.